Similarly, the unimolecular triple agonist SAR441255 (GLP‐1/GCG/GIP) outperforms dual agonists in preclinical studies, promoting weight loss and glucose regulation without exacerbating hyperglycemia [251]. Here, GLP1R is linked to Hyperglycemia.